



## **Adolore BioTherapeutics to Present Its Gene Therapy Program for Chronic Pain at the 4<sup>TH</sup> Annual National Institutes of Health (NIH) HEAL Initiative Investigator Meeting**

**DELRAY BEACH, FL.—February 21, 2023** – [Adolore BioTherapeutics, Inc.](#) (“Adolore” or the “Company”) a biotechnology company focused on developing breakthrough opioid-free pain relieving (analgesic) treatments for pain, today announced that [Dr. Roy C. Levitt](#), the Company’s founder, and Executive Chairman, will present at the [4<sup>th</sup> Annual NIH HEAL Initiative Investigator Meeting](#) taking place February 21-22, 2023. The NIH HEAL (Helping to End Addiction Long-Term) Initiative is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis from all angles.

As part of his presentation, Dr. Levitt will discuss the Company’s gene therapy program for chronic pain associated with moderate-to-severe knee osteoarthritis. The presentation will take place on Wednesday, February 22, 2023 at 1:55 PM ET as part of the *Innovative Therapeutic Strategies for Pain and Opioid Use Disorder* session.

The Company’s preclinical development of its gene therapy for chronic knee pain is supported by a UG3 HEAL grant awarded by the NIH. The Company has achieved proof-of-concept efficacy data in animal models, validating the analgesic mechanism-of-action to treat various forms of chronic pain including knee osteoarthritis (OA) and neuropathic pain. Adolore is developing the CMC and regulatory strategies to be reviewed with FDA prior to IND filing.

### **About the NIH HEAL Initiative®**

The NIH HEAL Initiative® will bring together HEAL funded researchers, federal officials, people with lived experience, and other stakeholders to share research findings, explore trends and shared interests, and identify opportunities to advance the goals of the initiative.

The meeting will include panels, scientific symposia, discussion groups, networking, and poster sessions for in-person and virtual attendees. Plenary

sessions will be available for the public to view via NIH VideoCast. For more information, visit the event website [here](#).

### **About Adolore BioTherapeutics, Inc.**

Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for the treatment of chronic pain and other pain and nervous system conditions or disorders. Our best-in-class lead programs are long-acting locally acting gene-therapies that are opioid-free Disease Modifying Anti-Pain therapies (DMAPs) for the treatment of a variety of chronic pain indications.

The Company's two current CA8\* gene therapy programs are in preclinical development for treatment of patients suffering from erythromelalgia, a life-long heritable chronic pain condition representing an orphan drug disease with no approved therapy, and chronic osteoarthritis knee pain, affecting a large number of patients that is often treated with opioids due to the lack of alternatives, thus contributing to the ongoing opioid crisis.

For more information, visit [adolore.com](http://adolore.com).

### **Forward Looking Statements**

To the extent this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words "believe," "expect," "anticipate," "intend," "estimate," "project," "will," "should," "may," "plan," "intend," "assume" and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements, because they involve known and unknown risks, uncertainties and other factors, some of which are beyond the control of the Company. These risks and uncertainties include, but are not limited to, those associated with drug development. These risks, uncertainties and other factors may cause the actual results, performance or achievements of the Company to be materially different from the anticipated future results, performance or achievements expressed or implied by the forward-looking statements.

### **Investor Relations Contact**

JTC Team, LLC

Jenene Thomas  
833-475-8247  
[adolore@jtcir.com](mailto:adolore@jtcir.com)